Product Banner

World In-vitro Fertilization (IVF) Services Market - Opportunities and Forecasts, 2014 - 2021

World In-vitro Fertilization (IVF) Services Market - Opportunities and Forecasts, 2014 - 2021
$4,830.00
$4,830.00
  • Jan 06, 2015
  • 416 pages
  • Allied Market Research
Abstract
IVF procedures have emerged as a preferable choice for the fertility treatments in clinical industry. The market is poised to witness a remarkable growth, primarily due to the related technological advancements such as pre-implantation genetic diagnosis (PGD) and three-parent IVF procedures.

The global IVF market is expected to reach $11.3 billion by 2021, at a CAGR of 10.8% from 2015 to 2021. Reduction in conception rates mainly in women aged 40 years or above, delayed pregnancy in women suffering from gynecological conditions, changing lifestyle and fertility disorders are the major factors that drive the market growth. Other factors responsible for the market growth are favorable reimbursement scenario and the delayed parenthood opted by couples due to professional and financial constraints. On the other hand, ethical concerns in particular countries, high cost of the IVF procedures and low awareness, especially in under-developed economies such as Nigeria are likely to restrain the market growth.

The rising initiatives towards commercialization of cost-efficient treatments and emerging medical tourism, mainly in developing nations would offer lucrative growth opportunities for IVF service providers in future. Further, the growing clinical research initiatives for the development of novel IVF technologies would provide a platform for growth of the global IVF market.

To provide a detailed market assessment, the report segments the global IVF market based on end-users and geography. The end-users IVF market is categorized into fertility clinics, hospitals, surgical centers and clinical research institutes. Fertility clinics and hospitals were the leading end-user segments globally, accounting for around three-fourths of the market in 2014. Geographically, the market is segmented across North America, Europe, Asia Pacific and LAMEA regions. In terms of number of IVF cycles performed, the Asia-Pacific region dominates the global IVF market. Asia Pacific IVF market is set to grow at a promising CAGR of 13.3% from 2015 to 2021, due to the factors such as wide availability of IVF clinics, high IVF success rates and the rising trend of fertility tourism. In Asia-Pacific region, China is the leading country accounting for majority of the market share and is expected to maintain its position during the analysis period. In terms of revenue, North America dominates the global IVF market, owing to the favorable reimbursement scenario. The market is expected to reach around $3.6 billion by 2021, at a CAGR of 11.2% over the forecast period.

Key Benefits

The report provides an in-depth analysis of the IVF market across twenty major countries with a cross sectional analysis of the number of IVF cycles performed, and total revenue generated during the forecast period
The report helps in understanding the strategies adopted by various IVF clinics and hospitals, in order to gain a higher market share in the global IVF market
Region-wise and country-wise in the global IVF market are comprehensively analyzed in the report
The projections in the report are made by analyzing the current market trends and highlighting the market potential for the period of 2014–2021, in terms of value and volume
Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework
Key Market Segments

The global IVF market is segmented based on end-users and geography:

MARKET BY END USERS

Fertility Clinics
Hospitals
Surgical centers
Clinical research institutes
MARKET BY END USER COUNTRY LEVEL ANALYSIS (VALUE & VOLUME)

United States
Canada
Mexico
United Kingdom
Germany
France
Italy
Spain
Denmark
Russia
China
India
Japan
Australia
New Zealand
Korea
Thailand
Latin America
Middle East
Africa


MARKET BY GEOGRAPHY (VALUE & VOLUME)

North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Denmark
Russia
Others Europe
Asia-Pacific
China
India
Japan
Australia
New Zealand
Korea
Thailand
Others APAC
LAMEA
Latin America
Middle East
Africa
Table of Contents
Chapter: 1 INTRODUCTION
1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments
1.4 Research Methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models



$0(SU)
Chapter: 2 EXECUTIVE SUMMARY


$506(SU)
Chapter: 3 WORLD IN VITRO FERTILIZATION (IVF) MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 IVF pricing trends by country
3.3 IVF Cycles by Country
3.4 Global IVF Market by End Users

3.4.1 Fertility clinics
3.4.2 Hospitals
3.4.3 Surgical centers
3.4.4 Clinical research institutes

3.5 Global IVF Market by Cycle Type

3.5.1 Fresh IVF cycles (non-donor)
3.5.2 Thawed IVF cycles (non-donor)
3.5.3 Donor egg IVF cycles

3.6 Market Dynamics

3.6.1 Drivers

3.6.1.1 Delayed pregnancies
3.6.1.2 Rise in global infertility rates
3.6.1.3 Emergence of new fertility tourism destinations

3.6.2 Restraints

3.6.2.1 High Cost involved in the treatment
3.6.2.2 Low level of awareness in developing economies
3.6.2.3 Inadequate reimbursements policies for IVF treatments
3.6.2.4 Ethical Considerations

3.6.3 Opportunities

3.6.3.1 relaxing the legal considerations on ivf treatments
3.6.3.2 New technology development and treatment options
3.6.3.3 Three parent IVF

3.7 Key Findings



$632(SU)
Chapter: 4 NORTH AMERICA IVF MARKET
4.1 United States IVF Market, (Revenue and Number of Cycles)

4.1.1 Number of Infertility Clinics, 2014
4.1.2 United States IVF Market by End Users

4.1.2.1 Fertility clinics
4.1.2.2 Hospitals
4.1.2.3 Surgical centers
4.1.2.4 Clinical research institutes

4.1.3 United States IVF market by cycle type

4.1.3.1 Fresh IVF cycles (non-donor)
4.1.3.2 Thawed IVF cycles (non-donor)
4.1.3.3 Donor egg IVF cycles

4.1.4 Drivers

4.1.4.1 Increasing popularity of IVF in United States
4.1.4.2 Increased rate of infertility and practices of embryo banking cycles

4.1.5 Restraints

4.1.5.1 High cost of IVF treatment in United Sates
4.1.5.2 Restrictions on 3-parent IVF treatments
4.1.5.3 Scattered Reimbursements

4.1.6 Regulatory Issues, Legislations and Authorities
4.1.7 Insurance Reimbursement Scenario
4.1.8 Company Profile

4.1.8.1 Fertility and Gynecology Center Monterey Bay IVF
4.1.8.2 Conceptions Reproductive Associates
4.1.8.3 Servy Massey Fertility Institute
4.1.8.4 Sher Institute for Reproductive Medicine (SIRM)
4.1.8.5 Cardone Reproductive Medicine & Infertility
4.1.8.6 Fertility Center of San Antonio
4.1.8.7 Houston Fertility Center
4.1.8.8 New hope fertility center
4.1.8.9 Reproductive Medicine Associates Of New Jersey

4.2 Canada IVF Market (Revenue and Number of Cycles)

4.2.1 Number of infertility centers
4.2.2 Canada IVF Market by End users

4.2.2.1 Fertility clinics
4.2.2.2 Hospitals
4.2.2.3 Surgical centers
4.2.2.4 Clinical research institutes

4.2.3 Canada IVF market by cycle type

4.2.3.1 Fresh IVF cycles (non-donor)
4.2.3.2 Thawed IVF cycles (non-donor)
4.2.3.3 Donor egg IVF cycles

4.2.4 Market Dynamics

4.2.4.1 Drivers

4.2.4.1.1 COMMERCIALIZATION OF IVF BOOSTER IN CANADA

4.2.4.2 Restraints

4.2.4.2.1 HIGH COST OF IVF IN CANADA

4.2.5 Regulatory Issues, Legislations and Authorities
4.2.6 Insurance Reimbursement Scenario
4.2.7 Company Profile

4.2.7.1 Toronto Centre for Advanced Reproductive Technology Ltd.
4.2.7.2 Fertility Treatment Center
4.2.7.3 Montreal Fertility Center

4.3 Mexico IVF Market (Revenue and Number of Cycles)

4.3.1 Number of infertility centers
4.3.2 Mexico IVF Market by End Users

4.3.2.1 Fertility clinics
4.3.2.2 Hospitals
4.3.2.3 Surgical centers
4.3.2.4 Clinical research institutes

4.3.3 Mexico IVF market by cycle type

4.3.3.1 Fresh IVF cycles (non-donor)
4.3.3.2 Thawed IVF cycles (non-donor)
4.3.3.3 Donor egg IVF cycles

4.3.4 Market Dynamics

4.3.4.1 Drivers

4.3.4.1.1 FERTILITY TOURISM
4.3.4.1.2 COMPARATIVELY LOW COST OF IVF

4.3.4.2 Restraints

4.3.4.2.1 LANGUAGE BARRIERS

4.3.5 Regulatory Issues, Legislations and Authorities
4.3.6 Insurance Reimbursement Scenario
4.3.7 Company Profile

4.3.7.1 Liv Fertility Center In Puerto Vallarta
4.3.7.2 BFC Biofertility Center



$1264(SU)
Chapter: 5 EUROPE IVF MARKET (REVENUE AND NUMBER OF CYCLES)
5.1 Germany IVF Market (Revenue and Number of Cycles)

5.1.1 Number of infertility clinics in Germany
5.1.2 Germany IVF Market by End Users

5.1.2.1 Fertility clinics
5.1.2.2 Hospitals
5.1.2.3 Surgical centers
5.1.2.4 Clinical research institutes

5.1.3 Germany IVF market by cycle type

5.1.3.1 Fresh IVF cycles (non-donor)
5.1.3.2 Thawed IVF cycles (non-donor)

5.1.4 Market Dynamics

5.1.4.1 Drivers

5.1.4.1.1 SUBSIDIZING IVF TREATMENTS
5.1.4.1.2 DELAYED MARRIAGES AND PARENTHOOD DECISIONS

5.1.4.2 Restraints

5.1.4.2.1 LIMITED ADOPTION OF IVF METHODS

5.1.5 Regulatory Issues, Legislations and Authorities
5.1.6 Insurance Reimbursement Scenario
5.1.7 Company Profile

5.1.7.1 Heidelberg University Hospital
5.1.7.2 Klinikum Stuttgart
5.1.7.3 DRK Kliniken Berlin
5.1.7.4 University Medical Center Freiburg

5.2 France IVF Market (Revenue and Number of Cycles)

5.2.1 Number of infertility centers in France
5.2.2 France IVF Market by End Users

5.2.2.1 Fertility clinics
5.2.2.2 Hospitals
5.2.2.3 Surgical centers
5.2.2.4 Clinical research institutes

5.2.3 France IVF market by cycle type

5.2.3.1 Fresh IVF cycles (non-donor)
5.2.3.2 Thawed IVF cycles (non-donor)
5.2.3.3 Donor egg IVF cycles

5.2.4 Market Dynamics

5.2.4.1 Drivers

5.2.4.1.1 RISING ADOPTION OF IVF BABIES AMONG SAME GENDER POPULATION
5.2.4.1.2 LOWER RATES OF FERTILITY

5.2.4.2 Restraints

5.2.4.2.1 STRINGENT GOVERNMENT REGULATIONS

5.2.5 Regulatory Issues, Legislations and Authorities
5.2.6 Insurance Reimbursement Scenario
5.2.7 Company Profile

5.2.7.1 Clinique de la Muette
5.2.7.2 Hopital des metallurgists, hopital cochin

5.3 United Kingdom IVF Market (Revenue and Number of Cycles)

5.3.1 Number of infertility centers in United Kingdom
5.3.2 United Kingdom IVF Market by End Users

5.3.2.1 Fertility clinics
5.3.2.2 Hospitals
5.3.2.3 Surgical centers
5.3.2.4 Clinical research institutes

5.3.3 United Kingdom IVF market by cycle type

5.3.3.1 Fresh IVF cycles (non-donor)
5.3.3.2 Thawed IVF cycles (non-donor)
5.3.3.3 Donor egg IVF cycles

5.3.4 Drivers

5.3.4.1 Commercialization of three-parent IVF procedures
5.3.4.2 Supportive Regulations

5.3.5 Restraints

5.3.5.1 Ethical Considerations

5.3.6 Regulatory Issues, Legislations and Authorities
5.3.7 Insurance Reimbursement Scenario
5.3.8 Company Profile

5.3.8.1 Lister Fertility Clinic
5.3.8.2 The Bridge Center
5.3.8.3 Chelsea and Westminster Hospital (Assisted Conception Unit)

5.4 Italy IVF Market (Revenue and Number of Cycles)

5.4.1 Italy IVF market by End users

5.4.1.1 Fertility clinics
5.4.1.2 Hospitals
5.4.1.3 Surgical centers
5.4.1.4 Clinical research institutes

5.4.2 Italy IVF market by cycle type

5.4.2.1 Fresh IVF cycles (non-donor)
5.4.2.2 Thawed IVF cycles (non-donor)

5.4.3 Market Dynamics

5.4.3.1 Drivers
5.4.3.2 Restraints

5.4.3.2.1 BAN ON THE SURROGACY

5.4.4 Regulatory issues, legislations and authorities
5.4.5 Insurance Reimbursement Scenario
5.4.6 Company Profile

5.4.6.1 ARC-STER srl
5.4.6.2 RAPRUI
5.4.6.3 Centre for Reproductive Medicine-Napoli

5.5 Spain IVF Market (Revenue and Number of Cycles)

5.5.1 Spain IVF Market by End Users

5.5.1.1 Fertility clinics
5.5.1.2 Hospitals
5.5.1.3 Surgical centers
5.5.1.4 Clinical research institutes

5.5.2 Spain IVF Market by Cycle Type

5.5.2.1 Fresh IVF cycles (non-donor)
5.5.2.2 Thawed IVF cycles (non-donor)
5.5.2.3 Donor egg IVF cycles

5.5.3 Market Dynamics

5.5.3.1 Drivers

5.5.3.1.1 INCREASE IN THE NUMBER OF FOREIGN PATIENTS

5.5.3.2 Restraints

5.5.4 Regulatory Issues, Legislations and Authorities
5.5.5 Insurance Reimbursement Scenario
5.5.6 Company Profiles

5.5.6.1 IVF spain
5.5.6.2 Clnica EUGIN Barcelona

5.6 Denmark IVF Market (Revenue and Number Of Cycles)

5.6.1 Denmark IVF Market by End Users

5.6.1.1 Fertility clinics
5.6.1.2 Hospitals
5.6.1.3 Surgical centers
5.6.1.4 Clinical research institutes

5.6.2 Denmark IVF market by cycle type

5.6.2.1 Fresh IVF cycles (non-donor)
5.6.2.2 Thawed IVF cycles (non-donor)
5.6.2.3 Donor egg IVF cycles

5.6.3 Drivers

5.6.3.1 Increase in disposable income
5.6.3.2 Advances in IVF technology

5.6.4 Restraints
5.6.5 Regulatory Issues, Legislations and Authorities
5.6.6 Insurance Reimbursement Scenario
5.6.7 Company Profiles

5.6.7.1 Copenhagen Fertility Center
5.6.7.2 Storkklinik v/Nina Stork
5.6.7.3 Vitanova
5.6.7.4 trianglen fertility clinic
5.6.7.5 Nordica - Denmark, Copenhagen

5.7 Russia IVF Market (Revenue and Number of Cycles)

5.7.1 Russia IVF Market by End Users

5.7.1.1 Fertility clinics
5.7.1.2 Hospitals
5.7.1.3 Surgical centers
5.7.1.4 Clinical research institutes

5.7.2 Russia IVF market by cycle type

5.7.2.1 Fresh IVF cycles (non-donor)
5.7.2.2 Thawed IVF cycles (non-donor)
5.7.2.3 Donor egg IVF cycles

5.7.3 Drivers

5.7.3.1 Rising popularity of fertility tourism

5.7.4 Restraints

5.7.4.1 Inadequate reimbursement policies

5.7.5 Regulatory Issues, Legislations and Authorities
5.7.6 Insurance Reimbursement Scenario
5.7.7 Company Profiles

5.7.7.1 ava-peter clinic
5.7.7.2 md medical group
5.7.7.3 ivf russia (The International Centre of the Reproductive Medicines)

5.8 Other Europe IVF Market (Revenue and Number of Cycles)

5.8.1 Other Europe IVF Market by End Users

5.8.1.1 Fertility clinics
5.8.1.2 Hospitals
5.8.1.3 Surgical centers
5.8.1.4 Clinical research institutes

5.8.2 Drivers

5.8.2.1 Wide availability of reimbursements
5.8.2.2 Changes in Lifestyle

5.8.3 Restraints
5.8.4 Regulatory Issues, Legislations and Authorities
5.8.5 Insurance Reimbursement Scenario
5.8.6 Company Profiles

5.8.6.1 Gynaecoloqisch Centrum
5.8.6.2 centrum voor medische genetica
5.8.6.3 Infertility-Vestliitto



$1264(SU)
Chapter: 6 ASIA-PACIFIC IVF MARKET (REVENUE AND NUMBER OF CYCLES)
6.1 India IVF Market (Revenue and Number of Cycles)

6.1.1 India IVF Market by End Users

6.1.1.1 Fertility clinics
6.1.1.2 Hospitals
6.1.1.3 Surgical centers
6.1.1.4 Clinical research institutes

6.1.2 India IVF market by cycle type

6.1.2.1 Fresh IVF cycles (non-donor)
6.1.2.2 Thawed IVF cycles (non-donor)
6.1.2.3 Donor egg IVF cycles

6.1.3 Market Dynamics

6.1.3.1 Drivers
6.1.3.2 Restraints

6.1.4 Regulatory Issues, Legislations and Authorities
6.1.5 Insurance Reimbursement Scenario
6.1.6 Company Profile

6.1.6.1 Bourn Hall Clinic
6.1.6.2 Southend Fertility and IVF Centre
6.1.6.3 Morpheus IVF Fertility Center
6.1.6.4 Bloom Fertility Center
6.1.6.5 Manipal Ankur
6.1.6.6 Cloudnine
6.1.6.7 Nova IVI Fertility

6.2 China IVF Market (Revenue and Number of Cycles)

6.2.1 China IVF Market by End User

6.2.1.1 Fertility clinics
6.2.1.2 Hospitals
6.2.1.3 Surgical centers
6.2.1.4 Clinical research institutes

6.2.2 China IVF market by cycle type

6.2.2.1 Fresh IVF cycles (non-donor)
6.2.2.2 Thawed IVF cycles (non-donor)
6.2.2.3 Donor egg IVF cycles

6.2.3 Market Dynamics

6.2.3.1 Drivers

6.2.3.1.1 CHANGE IN LIFESTYLE

6.2.3.2 Restraints

6.2.3.2.1 ONE CHILD POLICY

6.2.4 Regulatory Issues, Legislations and Authorities
6.2.5 Insurance Reimbursement Scenario
6.2.6 Company profile

6.2.6.1 Reproductive and genetic Hospital Citic-Xiangya
6.2.6.2 Shenyang Hospital
6.2.6.3 Shandong Provincial Hospital
6.2.6.4 Centre for Reproductive Medicine

6.3 Japan IVF Market (Revenue and Number of Cycles)

6.3.1 Japan IVF Market by End-Users

6.3.1.1 Fertility clinics
6.3.1.2 Hospitals
6.3.1.3 Surgical centers
6.3.1.4 Clinical research institutes

6.3.2 Japan IVF market by cycle type

6.3.2.1 Fresh IVF cycles (non-donor)
6.3.2.2 Thawed IVF cycles (non-donor)

6.3.3 Market Dynamics

6.3.3.1 Drivers
6.3.3.2 Restraints

6.3.4 Regulatory Issues, Legislations and Authorities
6.3.5 Insurance Reimbursement Scenario
6.3.6 Company Profile

6.3.6.1 EMD Serono, Inc
6.3.6.2 IVF NAMBA Clinic
6.3.6.3 Iwaki Womens Clinic
6.3.6.4 Sanno Hospital

6.4 Australia IVF Market (Revenue and Number of Cycles)

6.4.1 Australia IVF Market by End Users

6.4.1.1 Fertility clinics
6.4.1.2 Hospitals
6.4.1.3 Surgical centers
6.4.1.4 Clinical research institutes

6.4.2 Australia IVF market by cycle type

6.4.2.1 Fresh IVF cycles (non-donor)
6.4.2.2 Thawed IVF cycles (non-donor)

6.4.3 Market Dynamics

6.4.3.1 Drivers
6.4.3.2 Restraints

6.4.3.2.1 EMOTIONAL AND PHYSICAL STRESS
6.4.3.2.2 NO GUARANTEE FOR THE SUCCESSFUL TREATMENTS
6.4.3.2.3 SURPLUS EMBRYOS

6.4.4 Regulatory Issues, Legislations and Authorities
6.4.5 Insurance Reimbursement Scenario
6.4.6 Company Profile

6.4.6.1 Genea Biomedx
6.4.6.2 Thermo Fisher Scientific Inc.
6.4.6.3 Virtus Health limited
6.4.6.4 Monash IVF
6.4.6.5 City Fertility center, brisbane
6.4.6.6 Flinders Fertility clinic

6.5 New Zealand IVF Market (Revenue and Number of Cycles)

6.5.1 New Zealand IVF Market by End users

6.5.1.1 Fertility clinics
6.5.1.2 Hospitals
6.5.1.3 Surgical centers
6.5.1.4 Clinical research institutes

6.5.2 New Zealand IVF Market by Cycle Type

6.5.2.1 Fresh IVF cycles (non-donor)
6.5.2.2 Thawed IVF cycles (non-donor)
6.5.2.3 Donor egg IVF cycles

6.5.3 Market Dynamics

6.5.3.1 Drivers
6.5.3.2 Restraints

6.5.4 Regulatory Issues, Legislations and Authorities
6.5.5 Insurance Reimbursement Scenario
6.5.6 Company Profiles

6.5.6.1 Fertility Associates
6.5.6.2 Fertility Plus
6.5.6.3 Repromed

6.6 Korea IVF Market (Revenue and Number of Cycles)

6.6.1 Korea IVF Market by End Users

6.6.1.1 Fertility clinics
6.6.1.2 Hospitals
6.6.1.3 Surgical centers
6.6.1.4 Clinical research institutes

6.6.2 Korea IVF market by cycle type

6.6.2.1 Fresh IVF cycles (non-donor)
6.6.2.2 Thawed IVF cycles (non-donor)
6.6.2.3 Donor egg IVF cycles

6.6.3 Market Dynamics

6.6.3.1 Drivers
6.6.3.2 Restraints

6.6.4 Regulatory Issues, legislations and Authorities
6.6.5 Insurance Reimbursement Scenario
6.6.6 Company Profiles

6.6.6.1 Cha General Hospital
6.6.6.2 MARIA Fertility Hospital

6.7 Thailand IVF Market (Revenue and number of Cycles)

6.7.1 Thailand IVF Market by End Users

6.7.1.1 Fertility clinics
6.7.1.2 Hospitals
6.7.1.3 Surgical centers
6.7.1.4 Clinical research institutes

6.7.2 Thailand IVF market by cycle type

6.7.2.1 Fresh IVF cycles (non-donor)
6.7.2.2 Thawed IVF cycles (non-donor)
6.7.2.3 Donor egg IVF cycles

6.7.3 Market Dynamics

6.7.3.1 Drivers

6.7.3.1.1 GOVERNMENT INITIATIVES
6.7.3.1.2 ECONOMIC CONSIDERATIONS
6.7.3.1.3 BOOST IN MEDICAL TOURISM

6.7.3.2 Restraints

6.7.3.2.1 COMPARATIVELY LOW SUCCESS RATE
6.7.3.2.2 ETHICAL ISSUES IN ALLOWING GENDER SELECTION

6.7.4 Regulatory Issues, legislations and Authorities
6.7.5 Insurance Reimbursement Scenario
6.7.6 Company Profiles

6.7.6.1 Bangkok Fertility Center
6.7.6.2 Siriraj Hospital
6.7.6.3 Ramathibodi Hospital
6.7.6.4 Perfect Woman Institute
6.7.6.5 Jetanin Institute for Assisted Reproduction

6.8 Other Asia-Pacific IVF Market (Revenue and Number of Cycles)

6.8.1 Other Asia-Pacific IVF Market by End Users

6.8.1.1 Fertility clinics
6.8.1.2 Hospitals
6.8.1.3 Surgical centers
6.8.1.4 Clinical research institutes

6.8.2 Drivers

6.8.2.1 Increase in disposable income
6.8.2.2 Advances in IVF technology
6.8.2.3 Decline in fertility rate

6.8.3 Restraints

6.8.3.1 Physical and emotional impact due to low success rate

6.8.4 Regulatory Issues, legislations and Authorities
6.8.5 Insurance Reimbursement Scenario
6.8.6 Company Profiles

6.8.6.1 Fertility Centre, Siloam Hospitals Surabana
6.8.6.2 CRM-MIA-Philippines
6.8.6.3 IVFAS



$1391(SU)
Chapter: 7 LAMEA IVF MARKET (REVENUE AND NUMBER OF CYCLES)
7.1 Latin America IVF Market (Revenue and Number of Cycles)

7.1.1 Number of Infertility Centers
7.1.2 Latin America IVF Market by End users

7.1.2.1 Fertility clinics
7.1.2.2 Hospitals
7.1.2.3 Surgical centers
7.1.2.4 Clinical research institutes

7.1.3 Latin America IVF market by cycle type

7.1.3.1 Fresh IVF cycles (non-donor)
7.1.3.2 Thawed IVF cycles (non-donor)
7.1.3.3 Donor egg IVF cycles

7.1.4 Drivers

7.1.4.1 Rising Medical Tourism in Latin American Countries
7.1.4.2 Permission for IVF treatments in Costa Rica

7.1.5 Restraints

7.1.5.1 High infant mortality rates in Brazil

7.1.6 Regulatory Issues, legislations and Authorities
7.1.7 Insurance Reimbursement Scenario
7.1.8 Profiles of Major Players

7.1.8.1 Clinica Anglo Americana
7.1.8.2 IVF Panama Centro De Reproduccion
7.1.8.3 Insemer
7.1.8.4 Almater Hospital
7.1.8.5 San Fernando Hospital

7.2 Middle East IVF Market (Revenue and Number of Cycles)

7.2.1 Number of infertility centers
7.2.2 Middle East IVF Market by End users

7.2.2.1 Fertility clinics
7.2.2.2 Hospitals
7.2.2.3 Surgical centers
7.2.2.4 Clinical research institutes

7.2.3 Middle East IVF market by Cycle Type

7.2.3.1 Fresh IVF cycles (non-donor)
7.2.3.2 Thawed IVF cycles (non-donor)
7.2.3.3 Donor egg IVF cycles

7.2.4 Market Dynamics

7.2.4.1 Drivers

7.2.4.1.1 HIGH-TECH CULTURE IN THE MIDDLE EAST COUNTRIES
7.2.4.1.2 AVAILABILITY OF REIMBURSEMENTS

7.2.4.2 Restraints

7.2.4.2.1 STRINGENT GOVERNMENT REGULATIONS IN MIDDLE EAST REGIONS

7.2.5 Regulatory Issues, Legislations and Authorities
7.2.6 Insurance Reimbursement Scenario
7.2.7 Company Profile

7.2.7.1 Cyprus IVF Centre
7.2.7.2 Al Bushra Medical Specialty Complex
7.2.7.3 Reproductive Medicine Unit at Corniche Hospital (Corniche Fertility center)
7.2.7.4 Trakya University Hospital ART Center

7.3 Africa IVF Market (Revenue and Number of Cycles)

7.3.1 Number of infertility centers
7.3.2 Africa IVF Market by End users

7.3.2.1 Fertility clinics
7.3.2.2 Hospitals
7.3.2.3 Surgical centers
7.3.2.4 Clinical research institutes

7.3.3 Africa IVF market by Cycle Type

7.3.3.1 Fresh IVF cycles (non-donor)
7.3.3.2 Thawed IVF cycles (non-donor)
7.3.3.3 Donor egg IVF cycles

7.3.4 Drivers

7.3.4.1 Low costs of IVF treatment
7.3.4.2 Rising Fertility Tourism in South Africa

$0(SU)
List of Figures
List of Tables
Companies Covered